BHC Bausch Health Companies Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 885590 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.8%
TTM net income YoY-332.3%
TTM EPS YoY-332.0%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin11.2%
Net margin-7.6%
FCF margin16.8%
EBITDA margin21.6%
Returns
ROE—
ROA-3.2%
ROIC (approx.)5.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets101.3%
Debt / equity—
Current ratio1.56x
Interest coverage0.78x
Cash quality & payout
Operating cash flow / net income-2.63x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.27B | $9.62B |
| R&D expense | $629.00M | $616.00M |
| SG&A expense | $3.44B | $3.30B |
| Operating income | $1.81B | $1.55B |
| Interest expense | $1.60B | $1.39B |
| Pretax income | $367.00M | $167.00M |
| Income tax | $247.00M | $239.00M |
| Net income | $157.00M | -$46.00M |
| EBITDA | $3.02B | $2.81B |
| EPS (basic) | 0.42 | -0.13 |
| EPS (diluted) | 0.42 | -0.13 |
| Weighted avg. shares (diluted) | 375.00M | 368.00M |
| Balance sheet | ||
| Cash & equivalents | $1.31B | $1.20B |
| Receivables | $2.35B | $2.14B |
| Inventory | $1.63B | $1.59B |
| Current assets | $6.16B | $5.77B |
| PP&E, net | $2.07B | $1.78B |
| Goodwill | $11.27B | $11.09B |
| Intangibles | $4.64B | $5.55B |
| Total assets | $26.37B | $26.52B |
| Current liabilities | $4.18B | $6.75B |
| Short-term debt | $225.00M | $2.67B |
| Long-term debt | $20.59B | $18.94B |
| Total debt | $20.82B | $21.62B |
| Total liabilities | $25.99B | $26.84B |
| Shareholders' equity | -$554.00M | -$1.28B |
| Net debt | $19.51B | $20.41B |
| Shares outstanding | 370.53M | 367.84M |
| Cash flow statement | ||
| Operating cash flow | $1.40B | $1.60B |
| Capital expenditure | $397.00M | $337.00M |
| Free cash flow | $1.00B | $1.26B |
| Investing cash flow | -$595.00M | -$454.00M |
| Financing cash flow | -$742.00M | -$868.00M |
| Depreciation & amortization | $1.21B | $1.27B |
| Stock-based compensation | $216.00M | $150.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.